| review article | Q7318358 |
| scholarly article | Q13442814 |
| P50 | author | Punita Ponda | Q96000023 |
| P2093 | author name string | Jillian Leigh Hochfelder | |
| P2860 | cites work | Severe repeated anaphylactic reactions to sublingual immunotherapy | Q45348758 |
| The effect of local nasal immunotherapy in allergic rhinitis: using strips of the allergen dermatophagoides pteronyssinus | Q46104089 | ||
| Grading local side effects of sublingual immunotherapy for respiratory allergy: speaking the same language | Q46632369 | ||
| Efficacy of sublingual allergen vaccination for respiratory allergy in children. Conclusions from one meta-analysis | Q47804869 | ||
| Efficacy and safety of oral immunotherapy in respiratory allergy to Parietaria judaica pollen. A double-blind study. | Q50873295 | ||
| Intralymphatic injections as a new administration route for allergen-specific immunotherapy. | Q51740102 | ||
| Epicutaneous allergen administration as a novel method of allergen-specific immunotherapy. | Q51811667 | ||
| Important aspects in management of allergic rhinitis: compliance, cost, and quality of life. | Q52005647 | ||
| Further evaluation of local intranasal immunotherapy with aqueous and allergoid grass extracts. | Q52686369 | ||
| Allergen immunotherapy: a practice parameter third update. | Q52712682 | ||
| A three-year double-blind placebo-controlled study with specific oral immunotherapy to Dermatophagoides: evidence of safety and efficacy in paediatric patients. | Q53854248 | ||
| Local nasal immunotherapy and bronchial hyperreactivity in seasonal allergic rhinitis: an observational pilot study. | Q53900661 | ||
| Immunologic effects of encapsulated short ragweed extract: a potent new agent for oral immunotherapy. | Q53984387 | ||
| Efficacy of subcutaneous and sublingual immunotherapy with grass allergens for seasonal allergic rhinitis: a meta-analysis-based comparison. | Q55056712 | ||
| Sub-lingual immunotherapy: world allergy organization position paper 2009. | Q55527154 | ||
| Sublingual immunotherapy for treating allergic conjunctivitis | Q24235657 | ||
| Sublingual immunotherapy for allergic rhinitis | Q24248657 | ||
| Efficacy of sublingual immunotherapy in asthma: systematic review of randomized-clinical trials using the Cochrane Collaboration method | Q33255883 | ||
| Sublingual immunotherapy for the treatment of allergic rhinoconjunctivitis and asthma: a systematic review | Q34335462 | ||
| Immune mechanisms of allergen-specific sublingual immunotherapy | Q34484071 | ||
| Economic impact and quality-of-life burden of allergic rhinitis | Q34546395 | ||
| Efficacy of sublingual immunotherapy in the treatment of allergic rhinitis in pediatric patients 3 to 18 years of age: a meta-analysis of randomized, placebo-controlled, double-blind trials | Q34561153 | ||
| Intralymphatic immunization enhances DNA vaccination. | Q34723827 | ||
| Allergic rhinitis and its impact on asthma. In collaboration with the World Health Organization. Executive summary of the workshop report. 7-10 December 1999, Geneva, Switzerland | Q34778060 | ||
| The efficacy of sublingual immunotherapy for house dust mites respiratory allergy: results of a GA2LEN meta-analysis | Q35005943 | ||
| Sublingual immunotherapy for allergic rhinitis: systematic review and meta-analysis | Q35970094 | ||
| Presentation of exogenous protein antigens by dendritic cells to T cell clones. Intact protein is presented best by immature, epidermal Langerhans cells | Q36356239 | ||
| Allergen immunotherapy in allergic respiratory diseases: from mechanisms to meta-analyses | Q36411170 | ||
| Allergen immunotherapy for allergic respiratory diseases | Q36864947 | ||
| Intralymphatic allergen administration renders specific immunotherapy faster and safer: a randomized controlled trial | Q36970017 | ||
| Metaanalysis of the efficacy of sublingual immunotherapy in the treatment of allergic asthma in pediatric patients, 3 to 18 years of age. | Q36977154 | ||
| Evidence of adherence to allergen-specific immunotherapy | Q37613394 | ||
| Epicutaneous/transcutaneous allergen-specific immunotherapy: rationale and clinical trials | Q37786494 | ||
| Allergen-specific immunotherapy for respiratory allergies: from meta-analysis to registration and beyond. | Q37802050 | ||
| Subcutaneous specific immunotherapy for seasonal allergic rhinitis: a review of treatment practices in the US and Europe | Q37803398 | ||
| Subcutaneous immunotherapy | Q37941210 | ||
| Novel routes for allergen immunotherapy: safety, efficacy and mode of action | Q37984572 | ||
| New directions in immunotherapy. | Q38073718 | ||
| Subcutaneous and sublingual immunotherapy for seasonal allergic rhinitis: a systematic review and indirect comparison | Q38096138 | ||
| Increased airways responsiveness in mice depends on local challenge with antigen | Q38511603 | ||
| Efficacy and safety of oral immunotherapy with short ragweed extract | Q39455312 | ||
| Epicutaneous allergen-specific immunotherapy ameliorates grass pollen-induced rhinoconjunctivitis: A double-blind, placebo-controlled dose escalation study | Q40309560 | ||
| Oral immunotherapy with short ragweed extract in a novel encapsulated preparation: a double-blind study | Q40648737 | ||
| Efficacy of grass-maize pollen oral immunotherapy in patients with seasonal hay-fever: a double-blind study | Q40792530 | ||
| High dose grass pollen tablets used for hyposensitization in hay fever patients. A one-year double blind placebo-controlled study | Q40794981 | ||
| Oral immunotherapy in birch pollen hay fever | Q40795031 | ||
| Treatment of pollinosis with pollen extracts by the method of cutaneous quadrille ruling | Q41001799 | ||
| Long-term follow-up of nasal immunotherapy to Parietaria: clinical and local immunological effects | Q42663566 | ||
| Direct intralymphatic injection of peptide vaccines enhances immunogenicity. | Q43596580 | ||
| Intralymphatic allergen-specific immunotherapy: an effective and safe alternative treatment route for pollen-induced allergic rhinitis | Q43959432 | ||
| Comparative clinical-immunological study of oral and subcutaneous immunotherapy in children with extrinsic bronchial asthma | Q45199115 | ||
| Targeted lymph node immunization can protect cats from a mucosal challenge with feline immunodeficiency virus. | Q45239329 | ||
| Intralymphatic immunotherapy for cat allergy induces tolerance after only 3 injections | Q57266970 | ||
| Local nasal immunotherapy in allergic rhinitis to Parietaria. A double-blind controlled study | Q67586802 | ||
| Oral immunotherapy with grass pollen in enterosoluble capsules. A prospective study of the clinical and immunological response | Q67660464 | ||
| A double-blind trial of oral immunotherapy for Artemisia pollen asthma with evaluation of bronchial response to the pollen allergen and serum-specific IgE antibody | Q68696676 | ||
| Oral immunotherapy of children with rhinoconjunctivitis due to birch pollen allergy. A double blind study | Q68899502 | ||
| Clinical and immunological effects of oral immunotherapy with a standardized birch pollen extract | Q69607400 | ||
| Local intranasal immunotherapy for grass-allergic rhinitis | Q70239063 | ||
| Local nasal immunotherapy for Dermatophagoides-induced rhinitis: efficacy of a powder extract | Q70711714 | ||
| Local intranasal immunotherapy for ragweed allergic rhinitis I. Clinical response | Q70798616 | ||
| Local nasal immunotherapy with extract in powder form is effective and safe in grass pollen rhinitis: a double-blind study | Q70916264 | ||
| Local nasal immunotherapy for birch allergic rhinitis with extract in powder form | Q70952076 | ||
| Preseasonal intranasal immunotherapy in birch-alder allergic rhinitis. A double-blind study | Q71604603 | ||
| Local intranasal immunotherapy with allergen in powder in atopic patients sensitive to Parietaria officinalis pollen | Q71795992 | ||
| A double-blind, placebo-controlled trial of local nasal immunotherapy in allergic rhinitis to Parietaria pollen | Q72236152 | ||
| Safety and efficacy of oral immunotherapy with standardized cat extract | Q72773346 | ||
| Local nasal immunotherapy with a powder extract for grass pollen induced rhinitis in pediatric ages: a controlled study | Q73029456 | ||
| Epidermal dendritic cells induce potent antigen-specific CTL-mediated immunity | Q73292937 | ||
| Nasal immunotherapy in pollen-sensitive children | Q73428449 | ||
| Protective mucosal immunity elicited by targeted lymph node immunization with a subunit SIV envelope and core vaccine in macaques | Q74468321 | ||
| [Allergenic group specificity & therapeutic consequences in asthma; specific desensitization method by epicutaneous route] | Q74508807 | ||
| Nasal immunotherapy at constant dosage: a double-blind, placebo-controlled study in grass-allergic rhinoconjunctivitis | Q74760768 | ||
| Once-daily sublingual allergen-specific immunotherapy improves quality of life in patients with grass pollen-induced allergic rhinoconjunctivitis: a double-blind, randomised study | Q79222907 | ||
| Anaphylaxis to multiple pollen allergen sublingual immunotherapy | Q79805861 | ||
| Anaphylactic shock because of sublingual immunotherapy overdose during third year of maintenance dose | Q80190158 | ||
| Anaphylaxis to sublingual immunotherapy | Q80190718 | ||
| Anaphylaxis by latex sublingual immunotherapy | Q80190723 | ||
| Optimal dose, efficacy, and safety of once-daily sublingual immunotherapy with a 5-grass pollen tablet for seasonal allergic rhinitis | Q81439241 | ||
| Children's compliance with allergen immunotherapy according to administration routes | Q81595002 | ||
| Improving the therapeutic index of CpG oligodeoxynucleotides by intralymphatic administration | Q81773143 | ||
| Epicutaneous Immunotherapy in Grass-Induced Allergic Rhinitis | Q82647689 | ||
| Anaphylactic reaction after the first dose of sublingual immunotherapy with grass pollen tablet | Q83365078 | ||
| Epicutaneous allergen administration: a novel approach for allergen-specific immunotherapy? | Q84862954 | ||
| Allergic rhinitis: Direct and indirect costs | Q85170977 | ||
| P275 | copyright license | Creative Commons Attribution-NonCommercial 3.0 Unported | Q18810331 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P921 | main subject | immunotherapy | Q1427096 |
| P304 | page(s) | 61-71 | |
| P577 | publication date | 2013-07-22 | |
| P1433 | published in | ImmunoTargets and therapy | Q27724782 |
| P1476 | title | Allergen immunotherapy: routes, safety, efficacy, and mode of action | |
| P478 | volume | 2 |
Search more.